Artificial Intelligence | Medtronic's Hugo Robotic System Completes First US Surgery
Senior Technology Correspondent · AI, startups & MeitY policy
Quick summary
Medtronic's Hugo robotic-assisted surgery system has performed its first U.S. commercial surgical case on . This development highlights the growing global adoption of AI and robotics in healthcare, with potential implications for medical advancements in countries like India.
Medtronic's Hugo Robotic System Completes First US Surgery
Medtronic's Hugo Robotic-Assisted Surgery (RAS) system completed its first U.S. commercial surgical case on , marking a significant step in the application of robotics in medical procedures. The milestone follows the system's recent FDA clearance for urologic surgical procedures in December 2025.
What Happened / Key Details
The procedure, a robotic-assisted prostatectomy, was successfully performed by Dr. Jihad Kaouk, professor and chair of the Glickman Urologic Institute and the Zegarac-Pollock Endowed Chair in Robotic Surgery at Cleveland Clinic. The patient was discharged the day after the surgery. This successful operation demonstrates the Hugo system's readiness for broader use in the United States, expanding access to minimally invasive surgery. The system leverages advanced AI and automation to enhance surgical precision and potentially improve patient outcomes.
Official Position / Company Statement
Medtronic officially announced the completion of this first U.S. commercial case, emphasizing the system's role in expanding patient access to minimally invasive surgical options. Rajit Kamal, vice president and general manager of Robotic Surgical Technologies within Medtronic’s Surgical business, stated that the future of surgery is about technology enabling surgical teams to deliver the best possible care for every patient. Dr. Kaouk also commented that the new technology allows for customized approaches for each patient case, exemplifying Cleveland Clinic's commitment to surgical innovation.
Timeline / What's Next
The Hugo RAS system received FDA clearance for urologic surgical procedures, including prostatectomy, nephrectomy, and cystectomy, on . This clearance was supported by data from the Expand URO Investigational Device Exception (IDE) study, which met its primary safety and effectiveness endpoints. Medtronic plans to pursue additional indications for the Hugo system in the U.S., with submissions for general and gynecologic surgical procedures expected to follow. The Hugo system is already available in over 35 countries globally and has been used in tens of thousands of procedures across various specialties.
Context / Background
Robotic-assisted surgery systems are increasingly vital in modern healthcare, offering enhanced precision and control for surgeons, which can lead to reduced invasiveness and potentially quicker patient recovery times. The U.S. leads in robotic surgery adoption, with approximately 80% of urologic abdominal surgeries already conducted with robotic assistance. The introduction of systems like Medtronic's Hugo aims to further increase the availability of these advanced surgical methods and provide choice for hospitals. Globally, the technology holds significant promise for advancing healthcare infrastructure and patient care.